Med BioGene Swings to Loss, Posts No Revenue for First-Half 2012 | GenomeWeb

NEW YORK (GenomeWeb News) – Med BioGene on Thursday reported that it swung to a loss from a profit for the first half of 2012.

The Vancouver, British Columbia-based molecular diagnostics developer also said that it recorded no revenues for the six months ended June 30, compared to revenues of C$593,714 (US$597,795) for the first half of 2011, all of which were derived from licensing deals.

Its net loss for the first half of 2012 was C$223,418, or C$.00 per share, compared to a profit of C$215,034, or C$.00 per share, for the first half of 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.